Dee Datta
Algemeen Directeur bij Switch Therapeutics, Inc.
Profiel
Dee Datta was the founder of Allozyne, Inc. founded in 2004 where she held the title of Vice President from 2004 to 2006.
Dr. Datta is also the founder of Switch Therapeutics, Inc. Dr. Datta's former jobs include Senior Director-Business Development at XOMA Corp., Principal at The Column Group LLC, and Vice President-Corporate Development at Forty Seven, Inc. Dr. Datta's education includes a doctorate from California Institute of Technology and an MBA from Stanford Graduate School of Business.
Actieve functies van Dee Datta
Bedrijven | Functie | Begin |
---|---|---|
Switch Therapeutics, Inc.
Switch Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope. | Algemeen Directeur | 28-03-2023 |
Eerdere bekende functies van Dee Datta
Bedrijven | Functie | Einde |
---|---|---|
XOMA CORPORATION | Corporate Officer/Principal | 31-08-2019 |
FORTY SEVEN, INC. | Corporate Officer/Principal | 01-12-2017 |
Allozyne, Inc.
Allozyne, Inc. Medical SpecialtiesHealth Technology Allozyne, Inc. operates as a biotechnology company that develops and manufactures pharmaceutical products. The firm focuses on manufacture of protein therapeutics for the medical need in autoimmune diseases and cancer. The company was founded by David A. Tirrell, Deepshikha Datta, and William A. Goddard, III in March 2004 and is headquartered in Seattle, WA. | Oprichter | 01-01-2006 |
XOMA CORPORATION | Corporate Officer/Principal | - |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Private Equity Investor | - |
Opleiding van Dee Datta
California Institute of Technology | Doctorate Degree |
Stanford Graduate School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
XOMA CORPORATION | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Allozyne, Inc.
Allozyne, Inc. Medical SpecialtiesHealth Technology Allozyne, Inc. operates as a biotechnology company that develops and manufactures pharmaceutical products. The firm focuses on manufacture of protein therapeutics for the medical need in autoimmune diseases and cancer. The company was founded by David A. Tirrell, Deepshikha Datta, and William A. Goddard, III in March 2004 and is headquartered in Seattle, WA. | Health Technology |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
Forty Seven, Inc.
Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Switch Therapeutics, Inc.
Switch Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope. | Health Technology |